Skip to main content
  • Saved

Commented on 's Post

Efficiency of human monocyte-derived suppressor cell-based treatment in graft-versus-host disease prevention while preserving graft-versus-leukemia effect

Efficiency of human monocyte-derived suppressor cell-based treatment in graft-versus-host disease prevention while preserving graft-versus-leukemia effect

Source :

https://doi.org/10.1080/2162402X.2021.1880046

ABSTRACT Immunosuppressive cell-based therapy is a recent strategy for controlling Graft- versus-Host Disease (GvHD). Such cells ought to maintain their suppressive function in inflammatory conditions and in the presence of immunosuppressive agents currently used in allogeneic hematopoietic cell transplantation (allo-HCT). Moreover, these therapies should not diminish the benefits of allo-HCT, the Graft- versus-Leukemia (GvL) effect.

  • 3 weeks 4 days
    Even though the therapeutic armamentarium for gvhd has expanded in recent years, it remains a huge unmet area of need and this cell based therapy could become an exciting future option